In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...

A daily oral GLP-1 pill can help people with obesity lose about 12% of their body weight, according to early data shared by drugmaker Eli Lilly today. The medication, called orforglipron, may be a ...

Eli Lilly (LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

“The results we got were as good as we can possibly achieve with an oral small molecule GLP-1," says Dr. Dan Skovronsky, ...

When it comes to compounded Ozempic and other semaglutides, Dr. Goulden adds that they are not identical to their ...

Some GPs are proving that diet and lifestyle programmes can achieve similar results to Mounjaro, Wegovy and Ozempic – without ...